12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Dextromethorphan/quinidine: Phase II started

Avanir began the double-blind, placebo-controlled, U.S. Phase II AVR-131 trial to evaluate oral AVP-923 twice daily for 10 weeks in up to 200 patients. Avanir markets AVP-923 as Nuedexta in the...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >